European regulators have good news for Amgen

You are here: Home > Central Coast Health Watch > Current Article

By Staff Report / Friday, March 23rd, 2018 / Comments Off on European regulators have good news for Amgen

Amgen received two recommendations from European regulators that would allow label changes to cardiovascular drug Repatha and biosimilar cancer treatment AB 980. The European Medicines Agency Committee for Medicinal Products for Human Use, or CHMP, released a positive opinion March 23 for Repatha, stating that it could help reduce the risk of heart attack or…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.